

AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Appln. No. 10/533,833 (Q101061)


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-10. (cancelled).

11. (currently amended) A compound represented by the formula:



wherein ring D represents a piperidine ring optionally further substituted with C₁₋₆ alkyl,
 E represents a phenyl group optionally substituted with a substituent selected from the group
 consisting of a halogen atom and C₁₋₆ alkyl, Z¹ represents a methylene group optionally
 substituted with a substituent selected from the group consisting of C₁₋₆ alkyl, C₁₋₆
 alkoxy carbonyl, oxo and phenyl, COCH₂, CH₂CO or SO₂, R^{1b} represents (i) a 2-thiazolyl
 group optionally substituted with C₁₋₆ alkyl, (ii) a 2-imidazolyl group optionally substituted with
 C₁₋₆ alkyl, (iii) a 2-pyridyl group optionally substituted with a substituent selected from the group
 consisting of C₁₋₆ alkyl, a halogen atom, C₁₋₆ alkylthio, phenyl and thienyl, R^{2b} represents an
 optionally halogenated C₁₋₆ alkyl group, and R³ represents (i) a C₃₋₈ cycloalkyl group, (ii) a
 phenyl group or (iii) a 5- to 10-membered aromatic heterocyclic group containing one or two

AMENDMENT UNDER 37 C.F.R. § 1.116

U.S. Appln. No. 10/533,833 (Q101061)

kinds of 1 to 4 hetero atoms selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to carbon atoms, which may be substituted with a substituent selected from the group consisting of a halogen atom, cyano, C_{1-6} alkyl optionally substituted with a halogen atom, C_{1-6} alkoxy optionally substituted with a halogen atom, C_{1-6} alkyl carbonylamino, a 5- or 6-membered aromatic heterocyclic group and C_{1-6} alkylthio, provided that 1) N-[1-benzyl-4-(thiazol-2-yl)-4-piperidinyl]-N-phenylpropionamide, 2) N-[1-benzyl-4-(thiazol-2-yl)-4-piperidinyl]-N-(2-fluorophenyl)propionamide, 3) N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-(2-fluorophenyl)propionamide, 4) N-[1-benzyl-4-(4,5-dimethylthiazol-2-yl)-4-piperidinyl]-N-(2-fluorophenyl)propionamide, 5) N-[1-benzyl-4-(4,5-dimethylthiazol-2-yl)-4-piperidinyl]-N-(2-fluorophenyl)propionamide, 6) N-[1-benzyl-4-(2-pyridinyl)-4-piperidinyl]-N-(2-fluorophenyl)propionamide, 7) N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-phenylpropionamide and 8) N-[1-benzyl-4-(2-pyridinyl)-4-piperidinyl]-N-phenylpropionamide are excluded, or a salt thereof.

12. (cancelled).

13. (original) The compound according to claim 11, wherein R^3 is a phenyl group.

14. (original) The compound according to claim 11, wherein E is a phenyl group optionally having a substituent at an ortho position or a meta position.

15. (original) The compound according to claim 11, wherein E is an unsubstituted phenyl group.

AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Appln. No. 10/533,833 (Q101061)

16. (previously presented) The compound according to claim 11, wherein R^{1b} is a 2-thiazolyl group optionally substituted with a C₁₋₆ alkyl group.

17. (original) The compound according to claim 11, wherein R^{1b} is a 4-methyl-2-thiazolyl group.

18. (withdrawn-previously presented) The compound according to claim 11, wherein R^{1b} is a 2-pyridyl group optionally substituted with a substituent selected from the group consisting of a C₁₋₆ alkyl group, a C₁₋₆ alkylthio group, a halogen atom, a C₆₋₁₄ aryl group and an aromatic heterocyclic group.

19. (withdrawn) The compound according to claim 11, wherein R^{1b} is a 6-methyl-2-pyridyl group.

20. (cancelled).

21. (original) The compound according to claim 11, wherein Z¹ is a methylene group.

22. (original) The compound according to claim 11, wherein R^{2b} is an optionally halogenated methyl group or ethyl group.

23. (original) The compound according to claim 11, wherein R^{2b} is a methyl group or a trifluoromethyl group.

AMENDMENT UNDER 37 C.F.R. § 1.116
U.S. Appln. No. 10/533,833 (Q101061)

24-25. (cancelled).

26. (previously presented) N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-2,2,2-trifluoro-N-phenylacetamide, N-[1-benzyl-4-(6-methyl-2-pyridinyl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(6-methyl-2-pyridinyl)-4-piperidinyl]-2,2,2-trifluoro-N-phenylacetamide, N-[1-(4-fluorobenzyl)-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-(2-methylphenyl)acetamide, N-[1-benzyl-4-(4-methylthiazol-2-yl)-4-piperidinyl]-N-(3-chlorophenyl)acetamide, N-[4-(4-methylthiazol-2-yl)-1-(2-thienylmethyl)-4-piperidinyl]-N-phenylacetamide, N-[1-benzyl-4-(1-methyl-1H-imidazol-2-yl)-4-piperidinyl]-N-phenylacetamide, or a salt thereof.

27. (cancelled).

28. (previously presented) A medicine comprising the compound according to claim 11 or 26 or a salt thereof.

29. (previously presented) A pharmaceutical composition for regulating neuromedin U receptor, which comprises the compound according to claim 11 or 26 or a salt thereof and a pharmaceutically acceptable carrier.